Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 14.57
ABMD's Cash-to-Debt is ranked higher than
65% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 1.84 vs. ABMD: 14.57 )
Ranked among companies with meaningful Cash-to-Debt only.
ABMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.95  Med: No Debt Max: No Debt
Current: 14.57
Equity-to-Asset 0.83
ABMD's Equity-to-Asset is ranked higher than
87% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. ABMD: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
ABMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.72  Med: 0.86 Max: 0.94
Current: 0.83
0.72
0.94
Interest Coverage N/A
ABMD's Interest Coverage is ranked higher than
73% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 83.04 vs. ABMD: N/A )
Ranked among companies with meaningful Interest Coverage only.
ABMD' s Interest Coverage Range Over the Past 10 Years
Min: 506.67  Med: No Debt Max: No Debt
Current: N/A
Piotroski F-Score: 4
Altman Z-Score: 38.47
Beneish M-Score: -2.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 19.53
ABMD's Operating Margin % is ranked higher than
89% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ABMD: 19.53 )
Ranked among companies with meaningful Operating Margin % only.
ABMD' s Operating Margin % Range Over the Past 10 Years
Min: -61.9  Med: -4.93 Max: 19.76
Current: 19.53
-61.9
19.76
Net Margin % 11.63
ABMD's Net Margin % is ranked higher than
80% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. ABMD: 11.63 )
Ranked among companies with meaningful Net Margin % only.
ABMD' s Net Margin % Range Over the Past 10 Years
Min: -69.44  Med: -5.22 Max: 49.36
Current: 11.63
-69.44
49.36
ROE % 12.64
ABMD's ROE % is ranked higher than
76% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: 3.48 vs. ABMD: 12.64 )
Ranked among companies with meaningful ROE % only.
ABMD' s ROE % Range Over the Past 10 Years
Min: -37.95  Med: -4.88 Max: 49.44
Current: 12.64
-37.95
49.44
ROA % 10.86
ABMD's ROA % is ranked higher than
86% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 0.81 vs. ABMD: 10.86 )
Ranked among companies with meaningful ROA % only.
ABMD' s ROA % Range Over the Past 10 Years
Min: -32.2  Med: -3.98 Max: 41.81
Current: 10.86
-32.2
41.81
ROC (Joel Greenblatt) % 113.32
ABMD's ROC (Joel Greenblatt) % is ranked higher than
94% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 7.00 vs. ABMD: 113.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -220.87  Med: -46.22 Max: 171.62
Current: 113.32
-220.87
171.62
3-Year Revenue Growth Rate 24.00
ABMD's 3-Year Revenue Growth Rate is ranked higher than
92% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. ABMD: 24.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 10.9 Max: 24
Current: 24
-7.1
24
3-Year EBITDA Growth Rate 48.10
ABMD's 3-Year EBITDA Growth Rate is ranked higher than
90% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. ABMD: 48.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.9  Med: 14.7 Max: 136.2
Current: 48.1
-55.9
136.2
3-Year EPS without NRI Growth Rate 31.90
ABMD's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ABMD: 31.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.4  Med: 13.2 Max: 304.6
Current: 31.9
-52.4
304.6
GuruFocus has detected 2 Warning Signs with Abiomed Inc $ABMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ABMD Guru Trades in Q1 2016

Columbia Wanger 137,717 sh (New)
Jim Simons 287,100 sh (+152.51%)
Paul Tudor Jones 2,600 sh (unchged)
PRIMECAP Management 5,535,290 sh (-2.15%)
» More
Q2 2016

ABMD Guru Trades in Q2 2016

Joel Greenblatt 3,013 sh (New)
Columbia Wanger 388,958 sh (+182.43%)
Jim Simons 621,723 sh (+116.55%)
Paul Tudor Jones Sold Out
PRIMECAP Management 5,006,490 sh (-9.55%)
» More
Q3 2016

ABMD Guru Trades in Q3 2016

Jim Simons 660,223 sh (+6.19%)
Joel Greenblatt Sold Out
PRIMECAP Management 4,708,590 sh (-5.95%)
Columbia Wanger 80,790 sh (-79.23%)
» More
Q4 2016

ABMD Guru Trades in Q4 2016

Steven Cohen 92,600 sh (New)
Chuck Royce 10,000 sh (New)
Columbia Wanger 311,535 sh (+285.61%)
PRIMECAP Management 4,676,630 sh (-0.68%)
Jim Simons 523,900 sh (-20.65%)
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:OTCPK:WILYY, NAS:MASI, OTCPK:CHEOY, OTCPK:CNVVY, NAS:NUVA, OTCPK:FSPKF, OTCPK:EKTAF, NAS:IART, OTCPK:GGNDF, NAS:WMGI, NYSE:NVRO, NYSE:GMED, NAS:LIVN, NYSE:VAR, NAS:ALGN, OTCPK:NHNKY, OTCPK:SONVY, NYSE:TFX, NAS:CYNO, NAS:INGN » details
Traded in other countries:AIO.Germany,
Abiomed Inc is engaged in providing mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients.

Abiomed Inc is a Delaware corporation incorporated on June 4, 1987. The Company is engaged in providing mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Companys product portfolio includes; Impella 2.5, Impella CP, Impella RP, AB5000, Symphony, and Impella 5.0 & Impella LD. The Companys Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute and to provide the flow and pressure needed to compensate for right heart failure. The Company manufactures & sells the AB5000 Circulatory Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company faces competition from Getinge (Maquet Cardiovascular), Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, Terumo Heart, Inc. and CardiacAssist Inc. The Companys business is subject to extensive federal, state, local and foreign regulation.

Ratios

vs
industry
vs
history
PE Ratio 109.48
ABMD's PE Ratio is ranked lower than
89% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 27.24 vs. ABMD: 109.48 )
Ranked among companies with meaningful PE Ratio only.
ABMD' s PE Ratio Range Over the Past 10 Years
Min: 22.02  Med: 99.72 Max: 615.5
Current: 109.48
22.02
615.5
PE Ratio without NRI 109.48
ABMD's PE Ratio without NRI is ranked lower than
90% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 28.18 vs. ABMD: 109.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.02  Med: 99.72 Max: 615.5
Current: 109.48
22.02
615.5
Price-to-Owner-Earnings 82.38
ABMD's Price-to-Owner-Earnings is ranked lower than
82% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.45 vs. ABMD: 82.38 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABMD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 44.38  Med: 101.26 Max: 201.19
Current: 82.38
44.38
201.19
PB Ratio 12.21
ABMD's PB Ratio is ranked lower than
93% of the 250 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. ABMD: 12.21 )
Ranked among companies with meaningful PB Ratio only.
ABMD' s PB Ratio Range Over the Past 10 Years
Min: 1.58  Med: 5.59 Max: 14.18
Current: 12.21
1.58
14.18
PS Ratio 12.67
ABMD's PS Ratio is ranked lower than
89% of the 252 Companies
in the Global Medical Devices industry.

( Industry Median: 3.24 vs. ABMD: 12.67 )
Ranked among companies with meaningful PS Ratio only.
ABMD' s PS Ratio Range Over the Past 10 Years
Min: 2.36  Med: 6.48 Max: 17.6
Current: 12.67
2.36
17.6
Price-to-Free-Cash-Flow 76.56
ABMD's Price-to-Free-Cash-Flow is ranked lower than
87% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 29.41 vs. ABMD: 76.56 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 22.85  Med: 61.58 Max: 665.41
Current: 76.56
22.85
665.41
Price-to-Operating-Cash-Flow 52.36
ABMD's Price-to-Operating-Cash-Flow is ranked lower than
88% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 20.17 vs. ABMD: 52.36 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.12  Med: 52.54 Max: 430.93
Current: 52.36
21.12
430.93
EV-to-EBIT 60.23
ABMD's EV-to-EBIT is ranked lower than
89% of the 137 Companies
in the Global Medical Devices industry.

( Industry Median: 21.56 vs. ABMD: 60.23 )
Ranked among companies with meaningful EV-to-EBIT only.
ABMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -305.5  Med: -8.5 Max: 599.9
Current: 60.23
-305.5
599.9
EV-to-EBITDA 56.36
ABMD's EV-to-EBITDA is ranked lower than
94% of the 142 Companies
in the Global Medical Devices industry.

( Industry Median: 16.07 vs. ABMD: 56.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -397.6  Med: -7.55 Max: 727.3
Current: 56.36
-397.6
727.3
Shiller PE Ratio 876.80
ABMD's Shiller PE Ratio is ranked lower than
96% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.99 vs. ABMD: 876.80 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABMD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 807.38  Med: 1677.57 Max: 12369
Current: 876.8
807.38
12369
Current Ratio 5.66
ABMD's Current Ratio is ranked higher than
89% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. ABMD: 5.66 )
Ranked among companies with meaningful Current Ratio only.
ABMD' s Current Ratio Range Over the Past 10 Years
Min: 3.18  Med: 6.22 Max: 15.95
Current: 5.66
3.18
15.95
Quick Ratio 5.12
ABMD's Quick Ratio is ranked higher than
90% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.64 vs. ABMD: 5.12 )
Ranked among companies with meaningful Quick Ratio only.
ABMD' s Quick Ratio Range Over the Past 10 Years
Min: 2.56  Med: 5.53 Max: 15.43
Current: 5.12
2.56
15.43
Days Inventory 160.21
ABMD's Days Inventory is ranked lower than
63% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 125.61 vs. ABMD: 160.21 )
Ranked among companies with meaningful Days Inventory only.
ABMD' s Days Inventory Range Over the Past 10 Years
Min: 138.81  Med: 154.05 Max: 314.91
Current: 160.21
138.81
314.91
Days Sales Outstanding 44.18
ABMD's Days Sales Outstanding is ranked higher than
83% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. ABMD: 44.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.18  Med: 56.52 Max: 87.14
Current: 44.18
44.18
87.14
Days Payable 80.47
ABMD's Days Payable is ranked higher than
66% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. ABMD: 80.47 )
Ranked among companies with meaningful Days Payable only.
ABMD' s Days Payable Range Over the Past 10 Years
Min: 60.98  Med: 97.03 Max: 218.64
Current: 80.47
60.98
218.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.30
ABMD's 3-Year Average Share Buyback Ratio is ranked higher than
51% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. ABMD: -3.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -4.8 Max: -1
Current: -3.3
-14.9
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 32.45
ABMD's Price-to-Net-Cash is ranked lower than
61% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 19.91 vs. ABMD: 32.45 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.29  Med: 10.72 Max: 73.96
Current: 32.45
1.29
73.96
Price-to-Net-Current-Asset-Value 20.41
ABMD's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 6.90 vs. ABMD: 20.41 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ABMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.08  Med: 6.43 Max: 22.88
Current: 20.41
1.08
22.88
Price-to-Tangible-Book 13.68
ABMD's Price-to-Tangible-Book is ranked lower than
86% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 4.05 vs. ABMD: 13.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1  Med: 5.78 Max: 16.32
Current: 13.68
1
16.32
Price-to-Intrinsic-Value-Projected-FCF 6.35
ABMD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
81% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. ABMD: 6.35 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABMD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.39  Med: 7.41 Max: 38.9
Current: 6.35
4.39
38.9
Price-to-Median-PS-Value 1.95
ABMD's Price-to-Median-PS-Value is ranked lower than
85% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. ABMD: 1.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 0.94 Max: 4.02
Current: 1.95
0.35
4.02
Price-to-Peter-Lynch-Fair-Value 4.38
ABMD's Price-to-Peter-Lynch-Fair-Value is ranked lower than
82% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ABMD: 4.38 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABMD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.31  Med: 4.21 Max: 35.22
Current: 4.38
2.31
35.22
Price-to-Graham-Number 8.16
ABMD's Price-to-Graham-Number is ranked lower than
92% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. ABMD: 8.16 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ABMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.99  Med: 5.8 Max: 15.52
Current: 8.16
2.99
15.52
Earnings Yield (Greenblatt) % 1.70
ABMD's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ABMD: 1.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 1.3 Max: 3.7
Current: 1.7
0.2
3.7
Forward Rate of Return (Yacktman) % 76.76
ABMD's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.96 vs. ABMD: 76.76 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -40.8  Med: -0.3 Max: 76.9
Current: 76.76
-40.8
76.9

More Statistics

Revenue (TTM) (Mil) $414.6
EPS (TTM) $ 1.07
Beta-0.47
Short Percentage of Float5.76%
52-Week Range $79.23 - 132.95
Shares Outstanding (Mil)43.54

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 454 627
EPS ($) 1.15 2.06
EPS without NRI ($) 1.15 2.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ABMD

Headlines

Articles On GuruFocus.com
6 Stocks That Beat the Market Oct 05 2016 
Alaska Air, Delta and NVR Make the 30-30 Club Apr 15 2016 
Panic-Proofing the Small Investor Aug 26 2015 
Impressive Numbers That Matter: Abiomed Inc (ABMD), Freescale Semiconductor Ltd (FSL), Apple Inc (AA Jan 28 2015 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 04 2011 
ABIOMED Inc. Reports Operating Results (10-Q) Aug 05 2010 

More From Other Websites
Abiomed Surpasses 50,000 Impella® Patients Treated in the United States Feb 23 2017
Abiomed Surpasses 50,000 Impella® Patients Treated in the United States Feb 23 2017
Abiomed Celebrates 2017 American Heart Month Feb 21 2017
ABIOMED, Inc. breached its 50 day moving average in a Bullish Manner : ABMD-US : February 17, 2017 Feb 17 2017
ETFs with exposure to ABIOMED, Inc. : February 14, 2017 Feb 14 2017
ABIOMED INC Financials Feb 09 2017
ABIOMED INC Files SEC form 10-Q, Quarterly Report Feb 03 2017
ETFs with exposure to ABIOMED, Inc. : February 2, 2017 Feb 02 2017
ABIOMED, Inc. :ABMD-US: Earnings Analysis: Q3, 2017 By the Numbers : January 30, 2017 Jan 30 2017
Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3 Jan 30 2017
Edited Transcript of ABMD earnings conference call or presentation 26-Jan-17 1:00pm GMT Jan 26 2017
Abiomed beats 3Q profit forecasts Jan 26 2017
Abiomed beats 3Q profit forecasts Jan 26 2017
Abiomed Inc Earnings Call scheduled for 8:00 am ET today Jan 26 2017
ABIOMED, Inc. breached its 50 day moving average in a Bullish Manner : ABMD-US : January 26, 2017 Jan 26 2017
ABIOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 26 2017
Q3 2017 Abiomed Inc Earnings Release - Before Market Open Jan 26 2017
Abiomed Announces Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year Jan 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)